[Advancement in endocrine therapy for breast cancer].
Endocrine therapy with certain effect is an important part of combined therapy for hormone receptor-positive breast cancer. The endocrine therapy for breast cancer has made progress with the development of new endocrine drugs. Now, tamoxifen is still the standard endocrine therapeutic drug for the premenopausal patients, but aromatase inhibitors can bring more benefit for the postmenopausal patients. Several large-scale clinical trials about aromatase inhibitors and medical ovarian ablation are ongoing and attract attention widely. This review overviewed the endocrine therapy for breast cancer, and mainly introduced its recent advancement.
Yang
Ming-Tian
MT
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China. yangmt@mail.sysu.edu.cn
Lian
Zhen-Qiang
ZQ
D000077384:Anastrozole; D000730:Androstadienes / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000077289:Letrozole; D009570:Nitriles / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use
D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D009570:Nitriles; D020845:Selective Estrogen Receptor Modulators; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; D000077289:Letrozole; C056516:exemestane